Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
- PMID: 14606504
- DOI: 10.1359/jbmr.2003.18.11.1932
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
Abstract
Histomorphometry and microCT of 51 paired iliac crest biopsy specimens from women treated with teriparatide revealed significant increases in cancellous bone volume, cancellous bone connectivity density, cancellous bone plate-like structure, and cortical thickness, and a reduction in marrow star volume.
Introduction: We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both cancellous and cortical bone in a subset of women enrolled in the Fracture Prevention Trial of postmenopausal women with osteoporosis after a mean treatment time of 19 months. This is the first report of a biopsy study after treatment with teriparatide having a sufficient number of paired biopsy samples to provide quantitative structural data.
Methods: Fifty-one paired iliac crest bone biopsy specimens (placebo [n = 19], 20 microg teriparatide [n = 18], and 40 microg teriparatide [n = 14]) were analyzed using both two-dimensional (2D) histomorphometry and three-dimensional (3D) microcomputed tomography (microCT). Data for both teriparatide treatment groups were pooled for analysis.
Results and conclusions: By 2D histomorphometric analyses, teriparatide significantly increased cancellous bone volume (median percent change: teriparatide, 14%; placebo, -24%; p = 0.001) and reduced marrow star volume (teriparatide, -16%; placebo, 112%; p = 0.004). Teriparatide administration was not associated with osteomalacia or woven bone, and there were no significant changes in mineral appositional rate or wall thickness. By 3D cancellous and cortical bone structural analyses, teriparatide significantly decreased the cancellous structure model index (teriparatide, -12%; placebo, 7%; p = 0.025), increased cancellous connectivity density (teriparatide, 19%; placebo, - 14%; p = 0.034), and increased cortical thickness (teriparatide, 22%; placebo, 3%; p = 0.012). These data show that teriparatide treatment of postmenopausal women with osteoporosis significantly increased cancellous bone volume and connectivity, improved trabecular morphology with a shift toward a more plate-like structure, and increased cortical bone thickness. These changes in cancellous and cortical bone morphology should improve biomechanical competence and are consistent with the substantially reduced incidences of vertebral and nonvertebral fractures during administration of teriparatide.
Similar articles
-
Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.J Bone Miner Res. 2007 Aug;22(8):1173-80. doi: 10.1359/jbmr.070413. J Bone Miner Res. 2007. PMID: 17451369
-
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.J Bone Miner Res. 2003 Mar;18(3):539-43. doi: 10.1359/jbmr.2003.18.3.539. J Bone Miner Res. 2003. PMID: 12619939 Clinical Trial.
-
Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide.J Bone Miner Res. 2007 Jun;22(6):841-8. doi: 10.1359/jbmr.070310. J Bone Miner Res. 2007. PMID: 17352652
-
Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):260-70. doi: 10.1111/j.1742-7843.2004.pto940602.x. Basic Clin Pharmacol Toxicol. 2004. PMID: 15228497 Review.
-
Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.Bone. 2007 Jun;40(6):1447-52. doi: 10.1016/j.bone.2006.09.008. Epub 2006 Oct 12. Bone. 2007. PMID: 17045858 Review.
Cited by
-
Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases.Osteoporos Int. 2012 Dec;23(12):2897-900. doi: 10.1007/s00198-012-2172-x. Epub 2012 Oct 18. Osteoporos Int. 2012. PMID: 23076681
-
Impact of Release Kinetics on Efficacy of Locally Delivered Parathyroid Hormone for Bone Regeneration Applications.Tissue Eng Part A. 2021 Feb;27(3-4):246-255. doi: 10.1089/ten.TEA.2020.0119. Epub 2020 Sep 10. Tissue Eng Part A. 2021. PMID: 32615861 Free PMC article.
-
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab.Osteoporos Int. 2020 Nov;31(11):2231-2241. doi: 10.1007/s00198-020-05502-0. Epub 2020 Jul 4. Osteoporos Int. 2020. PMID: 32623487 Free PMC article. Clinical Trial.
-
PTH prevents the adverse effects of focal radiation on bone architecture in young rats.Bone. 2013 Aug;55(2):449-57. doi: 10.1016/j.bone.2013.02.023. Epub 2013 Mar 5. Bone. 2013. PMID: 23466454 Free PMC article.
-
Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing.J Clin Med. 2022 Dec 16;11(24):7477. doi: 10.3390/jcm11247477. J Clin Med. 2022. PMID: 36556093 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

